Chlormezanone

CHEMBL1200714 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
273.7 g/mol
LogP
1.1
Phase
4

A muscle relaxant and anxiolytic drug that was used for the short-term relief of muscle spasm and anxiety. It was withdrawn from worldwide markets in the 1990s due to reports of severe cutaneous reactions including toxic epidermal necrolysis and Stevens-Johnson syndrome. It is no longer available clinically.

Molekularmasse

273,7400 g/mol

LogP

1,10

TPSA

62,80 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Wirkmechanismus

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN1C(=O)CCS(=O)(=O)C1c1ccc(Cl)cc1

InChI

InChI=1S/C11H12ClNO3S/c1-13-10(14)6-7-17(15,16)11(13)8-2-4-9(12)5-3-8/h2-5,11H,6-7H2,1H3

Molecular Formula

C11H12ClNO3S

HBD / HBA

- / 3

Rotierbare Bindungen

1

Schwere Atome

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A muscle relaxant and anxiolytic drug that was used for the short-term relief of muscle spasm and anxiety. It was withdrawn from worldwide markets in the 1990s due to reports of severe cutaneous reactions including toxic epidermal necrolysis and Stevens-Johnson syndrome. It is no longer available clinically.

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Yes, Chlormezanone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200714. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2717. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.